MedPath

Clinical Trial News

Efficacy and Safety of Zihua Wenfei Granules in Treating Postinfectious Cough

A randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of Zihua Wenfei granules (ZHWFG) for treating postinfectious cough, specifically targeting the wind-cold invading lungs syndrome in traditional Chinese medicine. The study aims to assess the cough resolution and relief rates, alongside monitoring adverse events, across multiple centers in China.

Positive Phase 3 Data and New Glaucoma Treatments Highlight Advancements in Ophthalmology

  • A recent clinical trial achieved its primary visual acuity endpoints in both the US and EU/UK, demonstrating statistically significant near vision improvements over 8 hours.
  • Long-term analysis of a glaucoma treatment shows clinically and statistically significant reductions in intraocular pressure up to 36 months postoperatively.
  • Oxular initiated a Phase 2 trial in October 2024 for OXU-001, a therapeutic candidate targeting diabetic macular edema.

Sequana Medical's alfapump MOSAIC Study Results Published in Liver Transplantation

The results of the MOSAIC study, focusing on the utility, safety, and efficacy of the alfapump in managing recurrent and refractory ascites in liver disease patients, have been published in Liver Transplantation. The study highlights the alfapump's potential to improve quality of life and reduce the need for large-volume paracentesis in cirrhosis patients not suitable for TIPS.

Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)

NCT03973866Active, Not RecruitingNot Applicable
Sequana Medical N.V.
Posted 9/16/2019

Global Pricing Dilemma: The Complex Challenge of Valuing COVID-19 Vaccines

  • Pharmaceutical companies face unprecedented challenges in pricing COVID-19 vaccines, balancing global access needs with innovation rewards and sustainable development costs.
  • Early pricing discussions for COVID-19 treatments like remdesivir suggest potential vaccine prices could range from $2,000-$5,000 per course in developed markets, raising concerns about global accessibility.
  • Multiple factors including clinical efficacy, supply capabilities, competition, and government funding will influence final vaccine pricing, while maintaining public trust remains crucial for manufacturers.

Karyopharm Initiates Phase 1/2 Trial of Selinexor in Glioblastoma

  • Karyopharm Therapeutics has begun a Phase 1/2 clinical trial evaluating oral selinexor combined with standard care for newly diagnosed or recurrent glioblastoma (GBM).
  • The study aims to enroll approximately 400 patients across sites in the U.S., Europe, and Israel to assess the safety and efficacy of selinexor-based regimens.
  • The trial will explore selinexor in combination with radiation therapy, temozolomide, or lomustine, with progression-free survival and overall survival as primary endpoints.
  • Previous studies have indicated that selinexor crosses the blood-brain barrier and exhibits anti-GBM activity, supporting its further clinical development.

Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

NCT01986348TerminatedPhase 2
Karyopharm Therapeutics Inc
Posted 3/3/2014

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

NCT04421378TerminatedPhase 1
Karyopharm Therapeutics Inc
Posted 6/8/2020

Advancements in Neurology: From Hunter Syndrome to Alzheimer's Disease

Recent studies and trials in neurology have shown promising results across a range of conditions, including Hunter syndrome, Alzheimer's disease, and Dravet syndrome. Innovations in treatment and diagnostic tools are paving the way for more effective management of these complex conditions.

FTC Clears AbbVie's $63 Billion Allergan Acquisition with Asset Divestiture Requirements

  • The Federal Trade Commission has approved AbbVie's $63 billion acquisition of Allergan after requiring the divestiture of key assets to preserve competition in specific therapeutic markets.
  • AbbVie and Allergan must divest Allergan's EPI treatment drugs Zenpep and Viokace to Nestlé, as the companies currently control 95% of the exocrine pancreatic insufficiency drug market.
  • The companies are also required to transfer brazikumab, an investigational IL-23 inhibitor for Crohn's disease and ulcerative colitis, to AstraZeneca to maintain future competition in inflammatory bowel disease treatments.
  • The FTC's ten-month investigation involved reviewing over 430,000 documents and conducting more than 40 interviews to assess potential competitive harm to consumers.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.